

ASX ANNOUNCEMENT

23 June 2023

Despatch of Prospectus and Entitlement and Acceptance Form

23 June 2023 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce the despatch of the Prospectus and personalised Entitlement and Acceptance Forms to Cann shareholders with a residential address in Australia or New Zealand (**Eligible Shareholders**) in relation to the Company's non-renounceable entitlement offer of one (1) new fully paid ordinary share (**New Shares**) at \$0.12 (12 cents) each for every four (4) existing fully paid ordinary shares held by Eligible Shareholders at 7:00 pm AEST on Tuesday, 20 June 2023 (**Record Date**), together with one (1) option for every two (2) New Shares subscribed for (**Offer**).

A letter to ineligible shareholders notifying them of the Offer and their inability to participate has also been despatched.

The Offer is now open, and the Offer website is available to Eligible Shareholders.

The Offer website can be accessed at <https://www.canngrouponlimited.com/home/>. A copy of the Prospectus and your online personalised Entitlement and Acceptance form are available on the Offer website. Eligible Shareholders should read the Prospectus in its entirety before deciding whether to participate in the Offer.

To accept the Offer via the Offer website, Eligible Shareholders will need to follow these steps:

Step 1: Access the Offer website via <https://www.canngrouponlimited.com/home/>.

Step 2: Enter your country of residence and accept the terms and conditions.

Step 3: Download the Prospectus and read it.

Step 4: Verify your details by entering your Securityholder Reference Number (SRN) or Holder Identification Number (HIN) and your postcode to access your personalised Entitlement and Acceptance Form.

Step 5: Complete the Entitlement and Acceptance Form online and make payment using BPAY and the unique payment reference numbers provided (for Eligible Shareholders with an Australian bank account) or using the electronic funds transfer (i.e., Direct Credit) details provided in your Entitlement and Acceptance Form (for Eligible Shareholders with a residential address in New Zealand only).

Alternatively, Eligible Shareholders who received or requested a hard copy Prospectus and personalised Entitlement and Acceptance Form may also accept the Offer:

- for Eligible Shareholders with an Australian bank account only, by:
 - completing and returning a hard copy of their personalised Entitlement and Acceptance Form together with payment by cheque, bank draft or money order in Australian dollars; or

- paying via BPAY® in accordance with the instructions on their personalised Entitlement and Acceptance Form (without needing to complete and return their personalised Entitlement and Acceptance Form); or
- for Eligible Shareholders with a residential address in New Zealand only, by paying via electronic funds transfer and then submitting their personalised Entitlement and Acceptance Form to the email address specified on their personalised Entitlement and Acceptance Form.

The closing date for the Offer is 5:00pm (AEST) Tuesday 18 July 2023.

For further information regarding the Offer please contact your stockbroker or professional adviser, or Ms Deborah Ambrosini, Cann Group Limited Chief Financial Officer and Company Secretary on +61 3 9095 7088.

Authorised for release by the Company Secretary, Cann Group Limited.

For all other information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Deborah Ambrosini
CFO and Company Secretary
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com